The Alternative Products Expo is coming to Miami March 14-16, 2024. A leading organizer of CBD & Hemp products, the Alternative Products Expo offers niche manufacturers and service providers a common forum to network and showcase their products.

The Alternative Product category includes a broad spectrum of herbal products, mood enhancers, vape products, energy boosts, cannabis derivatives, and dietary supplements, to name a few. As Florida is a major hub of alternate lifestyles and trendsetting products, Miami emerges as a suitable venue for the Expo.

ZJ Events hosts these events for the CBD community to present the newest product innovations and trends, and detailing important updates on evolving industry regulations. It’s an exciting learning experience in a safe and conducive environment, also offering exceptional show-exclusive deals.

A coveted event for smoke shop professionals, the Alternative Products Expo reveals the most innovative and unique products that shops can buy to stock their inventory. From kratom, vaping products, CBD products, glass & smoking accessories, to hemp derivatives and mushrooms, attendees can find a huge range of products. Discover innovations and the most trendy products, and connect with a vibrant community of common goals and lifestyles at the Alternative Products Expo.

Exhibitors can showcase their products at their booths to get discovered by key industry professionals to expand their market reach. Vendors will exhibit their products, unveil their brands, and connect with buyers, at a wealth of exhibit booths. The Alternative Products Expo features industry experts and leaders who will share their valuable insights on the latest market moves, innovations, and prospects.

The expo represents a great and easy opportunity to connect with a wider counterculture community and build robust networking ties. A meeting point for wholesalers, distributors, manufacturers, and buyers, this expo offers critical brand exposure that can help businesses reach their long-term ROI.

To know more, please visit https://altproexpo.com/

• Early-stage lending fell 44% year-over-year in the first six months of 2023 following Silicon Valley Bank collapse
• Demand for venture debt remains strong for companies that aim to preserve control, stay autonomous, and maintain flexibility over capital structure
• Hosted by DealFlow Events, The Venture Debt Conference on March 6, 2024, in New York City features 30+ experts, interactive panel discussions, and opportunities to meet with the largest group of dealmakers in the lending business
• Emerging venture debt lenders bring expertise to startups and new companies navigating complex financial arrangements
• Attendance is free for qualified C-level executives representing a venture-backed or emerging growth company

The collapse of Silicon Valley Bank (SVB last year had a  significant impact on the venture debt market, resulting in a 44% year-over-year drop in early-stage lending during the first six months of 2023. Despite SVB’s failure, demand for venture debt remained strong. What was initially a major debt hole has since been filled by lending firms offering high-level insights and technological expertise.

Venture debt is favored by many startups and high-growth companies – especially those that want to preserve control and maintain autonomy without giving up equity. Venture debt can also provide startups with predictable repayment schedules and interest rates, enabling them to optimize cash flow management while allocating resources toward strategic growth initiatives.

Despite the market rebound, not all venture debt lenders are equal. Interest rates, repayment structures, covenants, and industry expertise vary greatly among lenders, with risks that include overleveraging, restrictive terms, and equity dilution if warrants are exercised.

The good news is that the market has evolved significantly since SVB’s collapse. Emerging leaders in venture debt financing are bringing practical experience and industry knowledge to startups and new companies navigating the complexities of funding. By tapping into this wealth of expertise, startups can access invaluable resources to fuel growth initiatives, scale their businesses effectively, and optimize their capital structure.

“One possibility that venture debt could unlock for the tech startup ecosystem is serving as an additional pathway to raise funding,” notes a recent Deloitte report on the state of venture debt in 2024. “And it could work well both for the lender (less risky) and the borrower (access to funds of smaller ticket size). Beyond traditional VCs, venture debt could serve as an alternate asset class for tech startups to keep the innovation engine on.”

Learn more about non-dilutive financing strategies for startups and emerging growth companies at the Venture Debt Conference coming up March 6, 2024, in New York City. This one-day event features 30+ speakers, educational sessions, interactive panel discussions, and opportunities to meet with the largest group of dealmakers in the industry.

Discussions will cover a wide range of subjects, including deal terms, asset-backed lending, and financing options. You’ll also have numerous opportunities to connect with industry professionals and explore potential partnerships during networking breaks and a cocktail reception. Join us for this exceptional learning and networking opportunity at The Edison Ballroom, one of the most luxurious venues in Manhattan.

Attendance may be free for qualified C-level executives representing a venture-backed or emerging growth company.

Learn more about the Venture Debt Conference and review the full program agenda.

• Utah-based Diamond Lake Minerals is establishing its reputation as an innovator in digital assets and government-regulated security tokens through strategic partnerships and investments that strengthen its vertically integrated offerings
• DLMI’s suite of industry-agnostic subsidiaries serves as a gateway to digital asset investment by imbuing those subsidiaries with registered security token offerings that shareholders accustomed to real world assets can use to dip a toe into the emerging digital market
• DLMI recently invested in registered market infrastructure provider Avrio Worldwide, PBC, to provide itself with the trading engine technology necessary to “capture and scale market opportunities” in accordance with best practices that suit a regulated environment
• DLMI is also partnering with U.S. Securities and Exchange Commission (“SEC”)-registered digital asset exchange INX to provide heightened security to their digital offerings, avoiding some of the legal woes afflicting many crypto issuers 

Salt Lake City-based Diamond Lake Minerals (OTC: DLMI) recently entered a strategic investment that will help the digital asset development and SEC-registered security token company to build a regulated digital financial market infrastructure for its tokenization needs.

Avrio Worldwide, PBC, made the announcement Feb. 20 (https://ibn.fm/bXzEx), reporting that DLMI will acquire a 24 percent stake in Avrio. Avrio is the parent company of a suite of companies that includes Arkonis, the operator of a broker dealer and Alternative Trading System (“ATS”) in the United States.

The company’s ATS technology is designed to provide the trading engine for private market operators involved in the issuance and secondary trading of securities using the blockchain for a protocol-agnostic approach to settlement of their fintech solutions.

Diamond Lake was established in the 1950s as a mining resource company but has since transitioned to creating a powerful parent umbrella company for a wide variety of vertically integrated subsidiaries across all potential industries, imbuing those assets with SEC-registered security token offerings (“STOs”).

DLMI’s strategy therefore helps establish its real-world assets as a gateway to the digital asset market for investors who are newcomers to the emerging world of tokenization.

“With a state-of-the-art dFMI (digital financial market infrastructure) stack, Avrio is the financial services technology engine to enable the DLMI network of companies and projects, across many industries, including: financial services, real estate, media / entertainment / gaming / and sports, hospitality, consumer products, technology and aerospace, and education and healthcare, while unlocking access to liquidity and value for investors through a registered platform,” Diamond Lake CEO Brian J. Esposito stated as part of the Avrio announcement.

DLMI has partnered with SEC-registered security token exchange INX to ensure that trade is regulated according to U.S. government guidelines, eliminating the insecurity that has troubled many crypto-based transactions because of the SEC’s attempts to bring a legal system crackdown on unregulated companies pooling crypto assets in transactions designed to generate returns based on the crypto issuer’s efforts (https://ibn.fm/rtL1g).

“The current philosophy and model is not tokenizing the shares, but it’s actually tokenizing business units within our subsidiaries. So there’ll be an attachment to some revenue-generating mechanism within the subsidiaries that we would go out to the public markets with … and offer participation in those businesses to a global audience,” Esposito told the Cryptonized webcast last month (https://ibn.fm/SQEWG).

Arkonis provides “exchange management (‘EM’), order management (‘OM’), portfolio management (‘PM’) and client management (‘CM’) for transacting in registered securities, ETFs, and funds in public markets,” according to the Avrio announcement.

The blockchain-agnostic platform “enables clients to capture and scale market opportunities while creating standardization and best practices designed to prevent fraud, protect investors, and comply with know-your-customer and anti-money laundering compliance laws,” it states.

Avrio’s dFMI is available on the Abu Dhabi Global Markets Financial Services Regulatory Authority Digital Lab, which is a virtual environment hosted by the internationally renowned financial center and free zone in the United Arab Emirates that has become an attractive regulatory jurisdiction for digital asset companies (https://ibn.fm/toPie).

For more information, visit the company’s website at www.DiamondLakeMinerals.com or LinkedIn page at www.LinkedIn.com/company/Diamond-Lake-Minerals/.

In addition, for information on the company’s security token SEC regulated exchange partner INX, and the development of the INX Way, visit https://www.inx.co/inx-ebook/. This free security token bible, written with the SEC on the rollout of security tokens and the future of digital assets, will greatly deepen your understanding of security tokens.

NOTE TO INVESTORS: The latest news and updates relating to DLMI are available in the company’s newsroom at https://ibn.fm/DLMI

• By 2060, the older Asian population in the U.S. is expected to reach 8.5 million, making up 9% of the country’s elderly demographic, signaling a significant increase from 4% in 2014
• Astiva Health is leading the charge in creating essential healthcare solutions tailored for this expanding demographic, demonstrating a deep understanding of their unique healthcare needs
• Astiva Health has introduced groundbreaking programs, including language-specific healthcare services and wellness initiatives, specifically designed for the diverse aging Asian American community

Astiva Health is working serve the Asian American community, which is undergoing a considerable demographic shift, with a growing segment of the population requiring more healthcare and support. The company is proactively meeting the unique needs of this rapidly aging group by providing healthcare services that are culturally sensitive and honor the diverse traditions and values across Asian cultures.

An Urban Institute report highlights the overlooked segment of seniors within the Asian American community facing financial insecurity, despite the broader perception of financial and educational success. This demographic is projected to swell to 8.5 million by 2060, constituting 9% of the U.S.’s older population—a notable increase from its 4% representation in 2014.

Astiva Health’s commitment to culturally sensitive care acknowledges the importance of traditional values such as filial piety and communal living, which are prevalent across various Asian cultures. By offering comprehensive health plans that promote independence while respecting cultural practices, Astiva addresses the challenges of traditional caregiving structures.

Aware of the barriers faced by Asian American seniors, including language difficulties and economic disparities, Astiva Health is dedicated to providing affordable healthcare solutions. The company recognizes the necessity of addressing higher poverty rates among Asian American seniors with targeted interventions.

By investing in the growth of the community, Astiva Health taps into the rich cultural heritage of the Asian American elderly to foster programs that encourage intergenerational exchange and learning. This effort not only enhances the cultural fabric of the communities Astiva serves but also addresses isolation by fostering a supportive community network through initiatives like language-specific healthcare services and senior wellness programs.

As the Asian American population ages, Astiva Health remains at the forefront of tackling the broader societal challenges of aging, healthcare, and cultural integration. With a commitment to delivering high-quality, culturally responsive care, Astiva Health is building a legacy of support for elders from all backgrounds, ensuring they receive the healthcare they deserve. Through strategic initiatives and compassionate care, Astiva Health is shaping a future where the aging Asian American community can thrive with dignity and robust support.

For more information about Astiva Health’s culturally sensitive healthcare solutions, please visit www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva

• Astrotech reported financial results for the quarter ended December 31, 2023, recording year-to-date revenue of $1,540,000
• The company attributed the growth to the successful fulfillment of two significant purchase orders for the TRACER 1000(TM), the world’s first mass spectrometer-based explosive trace detectors (“ETD”), to customers in Romania
• Astrotech is focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries 1st Detect Corp., AgLAB Inc., Pro-Control Inc., and BreathTech Corp.
• The company and its subsidiaries are positioned to capitalize on burgeoning markets, including the global mass spectrometry market, expected to grow from an estimated $6.77 billion in 2024 to $9.17 billion by 2029

Astrotech (NASDAQ: ASTC), a science and technology development and commercialization company, focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries, recently released financial results for the three months ended December 31, 2023 (“Q2 2024”).

The company recorded a 512% jump in its year-to-date (“YTD”) revenue to $1,540,000 from $301,000 in the comparative period a year before. Astrotech attributed this growth primarily to two significant purchase orders for the TRACER 1000(TM) explosive trace detectors (“ETDs”) to customers in Romania, which the company, through 1st Detect Corp., successfully delivered on (https://ibn.fm/nh80b).

The subsidiary 1st Detect develops, manufactures, and sells mass-spectrometer-based trace detectors – including the TRACER 1000(TM), the world’s first mass spectrometer-based ETD – for use in the security and detection markets. It is one of Astrotech’s wholly owned subsidiaries formed to explore and capitalize on opportunities in disparate markets. The other subsidiaries include Astrotech Technologies Inc, AgLAB Inc., Pro-Control Inc., and BreathTech Corp.

A recent SNS Insider article (https://ibn.fm/6nCuS) confirms that “the Explosive Trace Detection Market is witnessing significant growth driven by increasing security concerns, particularly in transportation, critical infrastructure, and public spaces”.  Specifically, it indicates: “The Explosive Trace Detection Market, valued at USD 1137.50 million in 2022, is projected to achieve a significant milestone, reaching USD 2250.60 million by 2030.” This market is yet another fast-growing and important opportunity for 1st Detect and the superior mass spectrometry technology it offers. The article continues that “there is a growing demand for advanced ETD systems that offer higher sensitivity, faster detection times, and improved ease of use”, the very capabilities that 1^st Detect represents. In particular, 1st Detect holds an exclusive AMS Technology license from ATI for air passenger and cargo security applications.

For its part, AgLAB has developed a mass-spectrometer-based chemical analyzer, the AgLAB 1000 series, and the AgLAB Maximum Value Process(TM) (“AgLAB MVP for use in botanical distillation and specifically, the hemp and cannabis sectors. AgLAB uses its proprietary mass spectrometry instrumentation on the manufacturing floor to test and analyze distilled cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) oils quickly, easily, and continually, providing immediate information that not only maximizes potency but also improves the ending weight yields of every batch. According to AgLAB’s analysis, its mass spectrometers improve yields by an average of 34% (https://ibn.fm/OI897).

The U.S. cannabis market, which combines the recreational cannabis, medical cannabis, and therapeutic cannabis segments, is expected to experience significant growth in the coming years, according to Statista, reaching a projected $39.85 billion in revenue in 2024 and $67.15 billion by the end of 2028. The market is projected to grow at a CAGR of 13.93% during this forecast period (https://ibn.fm/pE5aV). Globally, the cannabis market is projected to reach revenue of $60.79 billion in 2024 and $102.90 billion by 2028, representing a CAGR of 14.06% (https://ibn.fm/nVjAS).

Beyond the U.S. cannabis and cannabinoids markets, Astrotech is positioned to capitalize on and benefit from the growth in the global mass spectrometry market, which is expected to grow from an estimated $6.77 billion in 2024 to $9.17 billion by 2029, representing a CAGR of 6.25%. “One of the major driving factors for the growth of the mass spectrometry market is the technological advancements in mass spectrometer devices,” wrote Mordor Intelligence in its report (https://ibn.fm/XmFDa).

Pro-Control subsidiary is expected to benefit from the global industrial automation and control systems market that is valued at USD 172.26 billion in 2022 with a compound annual growth rate (“CAGR”) of 10.5% from 2023 to 2030. The Pro-Control 1000(TM) mass spectrometer is designed to measure, test, and increase efficiencies in the chemical manufacturing processes.

Pro-Control MVP(TM) uses mass spectrometry instrumentation to monitor and control the fractional distillation of bulk chemicals using real-time in-process samples. “The Pro-Control subsidiary was launched late Q2 2024, and we look forward to introducing Pro-Control to chemical manufacturers who are using all types of distillation,” said Thomas B. Pickens, III, Astrotech’s Chairman, CEO, and CTO.

The BreathTech subsidiary is continuing its development of a breath analysis device that can provide early detection of lung diseases so that targeted antibiotics can be administered within minutes vs. days under current lab conditions. “The early BreathTech work was focused on COVID, but as vaccines were introduced and the effect of the disease outbreaks diminished, we have expanded our breath work to include other lung diseases that would benefit from early identification,” said Mr. Pickens.

The BreathTech subsidiary is continuing its development of a breath analysis device that can to provide early detection of lung diseases so that targeted antibiotics can be administered within seconds vs. days under current lab conditions. “The early BreathTest work was directed exclusively to COVID, but as the vaccines too effect and the disease outbreaks diminished, we have expanded our breath work to include other lung diseases that would benefit from early identification. The testing of these diseases is ongoing and we remain optimistic over our most recent results,” said Mr. Pickens.

For more information, visit the company’s website at www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

• Sigyn’s common stock, temporarily trading under the ticker symbol “SIGYD”, is set to revert back to its historic symbol “SIGY” on February 29, 2024.
• The company, as part of its 2023 Year-End Report, summarized its development of medical technologies that target to overcome clearly defined limitations in global health.
• During 2023, Sigyn expanded its line-up of medical technologies designed to enhance the benefit of cancer therapies. The company’s cancer treatment pipeline now includes ImmunePrep(TM), ChemoPrep(TM), and ChemoPure(TM).  
• The company believes the successful clinical advancement of Sigyn Therapy(TM) to treat pathogen-associated conditions beyond the reach of drugs, may offer a strategic competitive advantage within the dialysis industry.

Sigyn Therapeutics (OTCQB: SIGY, SIGYD), a development-stage medical technology company, has released its year-end 2023 financials and additionally disclosed the completion of a 1-for-40 reverse split of its common stock was implemented on January 31, 2024. As a result of this split, Sigyn’s common stock will trade under the ticker symbol “SIGYD” for 20 business days and revert to trading under its historic symbol “SIGY” on February 29, 2024.

According to the annual report filed by the company for the year ending December 31, 2023, Sigyn Therapeutics expanded its therapeutic candidates, introducing ImmunePrep(TM) to improve the delivery of immunotherapeutic antibodies to treat cancer. The company is also developing ChemoPrep(TM) and ChemoPure(TM) to optimize chemotherapy delivery and reduce treatment toxicity. The company further disclosed that clinical site locations for first-in-human studies for Sigyn Therapy(TM) have been identified. Sigyn Therapy(TM) is a novel blood purification technology to treat pathogen-associated conditions that are beyond the reach of drugs. (https://ibn.fm/ppTQT).

Sigyn Therapeutics is developing innovative medical technologies to address critical healthcare challenges. The company’s technologies show promise in improving patient outcomes across various medical conditions, presenting significant market opportunities in the healthcare sector.

Sigyn created each of its technologies with two prerequisites in mind:

1. The technology must overcome a clearly defined limitation in healthcare
2. The technology’s successful clinical advancement would offer a potential competitive advantage within an established therapeutic segment

Sigyn Therapy(TM) aims to treat pathogen-associated inflammatory conditions, including drug-resistant viral and bacterial infections, endotoxemia, and sepsis, which is a leading cause of hospital deaths in the US.  The novel blood purification technology is deployed on dialysis machines, and has been demonstrated to remove a broad-spectrum of relevant therapeutic targets human blood plasma.

The company believes the successful clinical advancement of Sigyn Therapy(TM) could offer a strategic competitive advantage within the dialysis industry. First-in-human studies call for the enrollment of dialysis dependent end-stage renal disease (“ESRD”) patients with endotoxemia and concurrent inflammation. These are untreatable conditions associated with cardiovascular disease, a leading cause of ESRD patient deaths. Endotoxemia and inflammation also underlie other common causes of ESRD mortality, including viral and bacterial infections that induce sepsis.

A strategy that extended the lives of ESRD patients may be of considerable value to the dialysis industry when considering that more than 550,000 individuals suffer from ESRD in the United States alone. (https://ibn.fm/lmDib).

The ImmunePrep(TM) platform introduces a strategy to enhance the performance of immunotherapeutic antibodies through the elimination of circulating decoys that sequester or block cancer treatment antibodies from reaching their intended tumor cell targets.   While more than 1,000 therapeutic antibodies are being evaluated in human studies, Sigyn believes the ImmunePrep(TM) platform establishes the first strategy to eliminate the circulating decoys that limit the benefit of these highly valued drug agents.

ChemoPrep(TM) and ChemoPure(TM) are designed to overcome a delivery limitation and reduce toxicity of chemotherapy. ChemoPrep(TM) reduces the circulating presence of interference factors that inhibit chemotherapy from being delivered to intended cancer cell targets, while ChemoPure(TM) eliminates off-target chemotherapy to reduce patient toxicity and minimize organ damage.

For more information, visit the company’s website at www.SigynTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://ibn.fm/SIGY

• Lexaria, a global innovator in drug delivery platforms, just announced $3.6 million in gross proceeds from its registered direct offering priced at the market
• The proceeds will go to critical R&D studies, patent, and legal costs, as well as general working capital purposes
• This is timely, given Lexaria’s resolve to double down on GLP-1 investigations for the 2024 calendar year

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that the registered direct offering for the purchase and sale of 1,558,443 shares of common stock at a purchase price of $2.31 – at the market under Nasdaq rules – per share yielded approximately $3.6 million in gross proceeds. This was offered by the company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-262402), and it opens Lexaria to important new opportunities for the 2024 calendar year (https://ibn.fm/SrGcx).

Most notably, Lexaria intends to use the net proceeds from this offering for research and development (“R&D”) studies, and the associated patent and legal costs. It also intends to use the funds for general working capital purposes, important for its current focus on GLP-1 clinical studies for the 2024 calendar year.

“Our R&D plans for 2024 are very tightly focused and will be concentrated mainly on GLP-1 investigations,” noted Chris Bunka, Lexaria’s CEO (https://ibn.fm/oo58J).

In 2023, Lexaria laid down the groundwork for its GLP-1 clinical studies. The company achieved positive interim and final human pilot study results using a single semaglutide dose of a Rybelsus(R) tablet to a matching dose of Rybelsus that had been processed with DehydraTECH (TM) processing technology enhancements.

“Frankly, the results surprised us with their level of positivity,” noted Mr. Bunka.

“It was found that DehydraTECH processing: delivered a statistically-significant higher proportion of the semaglutide, and did so more quickly (very typical of results for our technology); reduced the quantity and severity of unwanted side effects; and had a statistically-significant impact on blood sugar in general and much more effectively after eating a meal, than did Rybelsus,” he added.

These results inspired the confidence of Lexaria’s team. In addition, the FDA’s recognition of GLP-1 drugs, having offered approvals as recently as 2021 and 2022 due to its health benefits, incentivized Lexaria to double down on this specific study. Consequently, the $3.6 million could not have come at a better time. Mr. Bunka and the rest of Lexaria’s management are optimistic that with this focus, the team’s hard work will prove its worth this year.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Correlate Energy, a publicly traded distributed energy solutions company, just announced its strategic partnership with Carbonsight, an online decarbonization planning tool
• With the partnership, Correlate will empower building portfolio owners with the tools and resources that allow them to make easier informed decisions toward decarbonization
• Move also complements Carbonsight’s mission of providing businesses with financially viable and environmentally sustainable solutions

Correlate Energy (OTCQB: CIPI), a publicly traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation, just announced its strategic partnership with Carbonsight (by Autocase). This move brings together Carbonsight’s cutting-edge decarbonization planning software and Correlate’s expertise in developing and financing renewable and clean energy projects, together helping businesses transition to a low-carbon future (https://ibn.fm/YlIUO).

“By combining Carbonsight’s advanced decarbonization planning software with Correlate’s expertise in developing and financing energy projects, we are creating a powerful synergy that empowers businesses to navigate the transition to a low-carbon future with confidence,” noted Todd Michaels, Correlate’s CEO.

Carbonsight is an online decarbonization planning tool specifically designed for real estate portfolios. It facilitates the development of building and portfolio plans to achieve carbon reduction targets. This allows building portfolio owners to organize pertinent data, quantify prospective CO2-reducing solutions, and visualize carbon reduction scenarios to achieve emission reduction goals.

With the strategic partnership, Correlate will get to empower building portfolio owners with the tools and resources that would allow them to make informed, impactful decisions that have positive economic benefits and create clear plans towards decarbonization. More importantly, it will complement Carbonsight’s mission of providing businesses with financially viable and environmentally sustainable solutions.

“We are thrilled to join forces with Correlate in this strategic partnership,” noted John Williams, Carbonsight’s CEO.

“Together, we offer building owners a comprehensive and integrated solution for decarbonization planning through implementation, making the journey towards sustainability more seamless and impactful,” he added.

This partnership marks a great start to the year for Correlate. It also serves as a testament to its commitment to maintaining the momentum gained in the previous year, having closed the year with the commissioning of American Tire Distributors’ (“ATD”) Huntersville, North Carolina headquarters, as well as the commissioning of a solar project at Continental Envelope’s Geneva, Illinois manufacturing plant earlier in the year. It further shows its commitment to creating shareholder value, even as it pushes to assert its position as a leader in the market.

For more information, visit the company’s website at www.Correlate.Energy, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.Correlate.Energy/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.Correlate.Energy/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Activist investors target underperforming companies with an eye toward implementing agendas to maximize shareholder value
• Efforts by the SEC to limit activist interventions include proposals to shorten Schedule 13 filing deadlines, mandate amendments within a day of significant changes, and prevent shareholders from interfering with a company’s pro-ESG initiatives
• Activist investors tackle ongoing challenges by staying on top of emerging trends, adopting best practices, and forming strategic alliances
• DealFlow Events presents an unparalleled networking and learning opportunity: The Activist Investor Conference on March 21, 2024, in New York City
• Like all DealFlow events, this conference promises to deliver. The event features 20+ experts discussing topics covering value investing strategies, legal issues, corporate relations, and international opportunities

Activist investors remain a force to be reckoned with. They target companies perceived to be underperforming or inefficient and implement strategies to maximize shareholder value.

That’s why they’re also called value investors.

Indicators of underperformance that grab their attention include stagnant stock prices, low profitability, inefficient resource utilization, governance deficiencies, regulatory scrutiny, and operation in industries undergoing significant disruption.

A recent example is Disney, where activist investors are leveraging their influence to alter the company’s strategic direction and corporate governance. To boost content production for its Disney+ streaming service, shareholders pressured the company to redirect resources from its annual dividend toward streaming content. Value investors also advocated for changes in the Disney board composition and executive compensation structures.

Markets typically respond positively to activist involvement. A recent example is the acquisition of a stake in Salesforce by San Francisco-based ValueAct Capital Management. ValueAct’s involvement resulted in a 10% employee reduction at Salesforce and the appointment of its co-chief executive officer to the board. Salesforce shares turned around as a result of these interventions, surging by 57% during Q1-2023.

Value investing is also picking up speed in Europe. According to a recent survey of corporate executives and activist investors, activity surged last year with a notable increase in new players launching a record number of new public campaigns.

Attempts by the SEC to curb activist interventions include proposals to decrease initial Schedule 13 filing deadlines to five days and requiring amendments within a day of significant changes. The proposals also aimed to push filers to disclose derivative holdings and eliminate the requirement for investors to act in concert. Additional rules were suggested to prevent activist shareholders from obstructing a company’s pro-ESG initiatives.

Activist investors effectively tackle these challenges by staying on top of emerging trends, adopting best practices, and forming strategic alliances.

The Activist Investor Conference on March 21, 2024 in New York City is where investors, corporate governance experts, advisory firms, proxy solicitors, and board members will gather to gain insights and forge partnerships. This year’s event features 20+ experts presenting topics covering value investing strategies, legal issues, corporate relations, international opportunities and more.

As with all DealFlow Events, the Activist Investor Conference promises to deliver. Learn more and register.

Quant Strats invites thought leaders, c-suite representatives, and executives from all over the globe, for a flourishing debate and discussion on the key trends and changes in the industry, with a specific focus on real-life applications. The Quant Strats Conference, taking place March 12th, 2024, is the leading event for quantitative thought leaders, where you can network with a crowd of over 300 quant leaders to learn the latest market dynamics. Connect with over 50 speakers from reputed entities such as Goldman Sachs, Robeco, Point72, ADIA, and many more.

The Quant Strats summit provides a phenomenal platform for industry representatives to meet and network with a unique audience, gather informative data that gives them a competitive edge, as well as connect with leaders of great knowledge and connect. The event will host debates, presentations, and panels consisting of influential C-suite representatives who decide on the trends and actions that drive the industry.

Quant Strats has worked for the past 10 years to explore, research, and gather quantum data and investment opportunities for meaningful collaboration among the selling and buying sides of the industry. The topics of the agenda include:

• Determining the next source of alpha
• Finding new sources of data in a saturated marketplace
• Applying the new technologies of ML, AI, and NPL for investment and risk management
• Exploring, organizing, and employing actionable data for various purposes
• Synchronizing and streamlining different processes

As markets of North America and Europe return to normality, experts are on the lookout for the next source of Alpha and the relevant data for streamlining the processes. These quantitative leaders get together at the Quant Strats platform to understand ways of generating alpha, managing risks, and discovering the best opportunities that the markets have to offer.

To know more, please visit https://ibn.fm/2e3QR